Search Results for: "immunex v samsung bioepis etanercept"

Immunex and Samsung Bioepis Seek to Stay Etanercept Biosimilar Litigation (UPDATED)

This week, in the Immunex v. Samsung Bioepis BPCIA litigation regarding ETICOVO (etanercept-ykro), Samsung Bioepis’s biosimilar of ENBREL, the New Jersey district court entered a Consent Injunction Order that prohibits Samsung Bioepis from using, importing, offering to sell, or selling any etanercept product in the United States, except as allowed…

Read More

Samsung Bioepis Sued Regarding Its Recently-Approved Etanercept Biosimilar

Yesterday, Immunex, Amgen, and Hoffmann-LaRoche (collectively, “Plaintiffs”) filed a complaint in the District of New Jersey against Samsung Bioepis alleging patent infringement under the BPCIA based on Samsung Bioepis’ submission of an aBLA for a biosimilar of ENBREL® (etanercept).  As we reported yesterday, Samsung Bioepis recently received FDA-approval for that product,…

Read More

BPCIA Litigations

The table below chronologically lists the U.S. patent litigations filed under the BPCIA regarding aBLAs for biosimilar products. Currently pending cases are in red. # Litigation Accused Biosimilar [status] Reference Product Complaint Filed Status/Outcome District Court Appeal 1 Amgen v. Sandoz, No. 14-474 (N.D. Cal.) [consolidated with #7 below] ZARXIO (filgrastim-sndz)…

Read More